Westmead Breast Cancer Institute, Westmead Hospital, PO Box 143, Westmead, NSW, 2145, Australia.
Breast Cancer Res Treat. 2013 Jan;137(2):599-607. doi: 10.1007/s10549-012-2381-1. Epub 2012 Dec 14.
The objective of this study is to examine the association between vitamin D status and risk of breast cancer in an Australian population of women. The study design is observational case-control study, performed at Westmead Breast Cancer Institute, Westmead Hospital, Sydney, Australia. 214 women newly diagnosed with breast cancer were matched to 852 controls, and their blood samples were tested at the same laboratory between August 2008 and July 2010. Circulating 25-hydroxyvitamin D (25(OH)D) concentration, was defined as sufficient (≥75 nmol/L), insufficient (50-74 nmol/L), deficient (25-49 nmol/L) or severely deficient (<25 nmol/L). The difference in median 25(OH)D concentration between cases and controls was reported, and the Mann-Whitney U test was used to determine the significance of the difference. Odds ratios and 95 % confidence intervals for the risk of breast cancer were estimated by Cox regression. Median plasma 25(OH)D was significantly lower in cases versus controls overall (53.0 vs 62.0 nmol/L, P < 0.001) and during summer (53.0 vs 68.0 nmol/L, P < 0.001) and winter (54.5 vs 63.0 nmol/L, P < 0.001). Median 25(OH)D was also lower in cases when stratified by BMI (<30, ≥30) and age group (<50, ≥50 years) compared to matched controls, although the difference failed to reach statistical significance. In a Cox regression model, plasma 25(OH)D was inversely associated with the odds ratio of breast cancer. Compared to subjects with sufficient 25(OH)D concentration, the odds ratios of breast cancer were 2.3 (95 % CI 1.3-4.3), 2.5 (95 % CI 1.6-3.9) and 2.5 (95 % CI 1.6-3.8) for subjects categorised as severely deficient, deficient or insufficient vitamin D status, respectively. The results of this observational case-control study indicate that a 25(OH)D concentration below 75 nmol/L at diagnosis was associated with a significantly higher risk of breast cancer. These results support previous research which has shown that lower 25(OH)D concentrations are associated with increased risk of breast cancer.
本研究旨在探讨澳大利亚女性人群中维生素 D 状态与乳腺癌风险之间的关联。研究设计为观察性病例对照研究,在澳大利亚悉尼威斯特米德乳腺癌研究所威斯特米德医院进行。214 名新诊断为乳腺癌的女性与 852 名对照相匹配,并于 2008 年 8 月至 2010 年 7 月在同一实验室进行了血液样本检测。循环 25-羟维生素 D(25(OH)D)浓度定义为充足(≥75nmol/L)、不足(50-74nmol/L)、缺乏(25-49nmol/L)或严重缺乏(<25nmol/L)。报告了病例和对照组之间中位数 25(OH)D 浓度的差异,并使用曼-惠特尼 U 检验确定差异的显著性。通过 Cox 回归估计乳腺癌风险的比值比和 95%置信区间。总体而言,病例组与对照组相比,中位数血浆 25(OH)D 显著降低(53.0 与 62.0nmol/L,P<0.001),夏季(53.0 与 68.0nmol/L,P<0.001)和冬季(54.5 与 63.0nmol/L,P<0.001)。与匹配的对照组相比,根据 BMI(<30、≥30)和年龄组(<50、≥50 岁)分层后,病例组的中位数 25(OH)D 也较低,尽管差异未达到统计学意义。在 Cox 回归模型中,血浆 25(OH)D 与乳腺癌的比值比呈负相关。与具有足够 25(OH)D 浓度的受试者相比,严重缺乏、缺乏或不足维生素 D 状态的受试者患乳腺癌的比值比分别为 2.3(95%CI1.3-4.3)、2.5(95%CI1.6-3.9)和 2.5(95%CI1.6-3.8)。本观察性病例对照研究的结果表明,诊断时 25(OH)D 浓度低于 75nmol/L 与乳腺癌风险显著增加相关。这些结果支持先前的研究表明,较低的 25(OH)D 浓度与乳腺癌风险增加相关。